All Stories

  1. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis

    Article • Blood Pressure, August 2019, Taylor & Francis

    Prof Michel Burnier, giovanni bader, Mr Sharanbasappa Durg

  2. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2017, Dove Medical Press

    Dr. Konstantinos Kostikas, giovanni bader, Claus Vogelmeier

  3. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2017, Dove Medical Press

    Professor David Price, Dr. Konstantinos Kostikas, giovanni bader

  4. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2016, Dove Medical Press

    giovanni bader, Michael Humphries, Claus Vogelmeier

  5. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study

    Article • Vascular Health and Risk Management, February 2015, Taylor & Francis

    giovanni bader, Mahir Khalil Ibrahim Jallo

  6. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

    Article • Vascular Health and Risk Management, November 2014, Taylor & Francis

    Dr James E Foley, giovanni bader